Expanding Pediatric Market Recent FDA clearance for RELiZORB's expanded use in children aged 2 to 5 years highlights a growing market segment. This presents sales opportunities with pediatric hospitals, specialized clinics, and healthcare providers focused on early-onset gastrointestinal conditions.

Innovative Product Pipeline Alcresta's proprietary enzyme-based platform supports a broad pipeline targeting gastrointestinal and rare diseases, offering multiple potential products for partnerships or sales expansion into niche markets that require specialized nutritional solutions.

Strong Clinical Validation Publication of clinical data and award recognition for RELiZORB demonstrate product efficacy and market credibility, making it easier to approach healthcare providers and insurance payers for adoption and reimbursement opportunities.

Focused Rare Disease Solutions Dedicated to addressing challenges in gastrointestinal and rare diseases, Alcresta’s targeted approach creates opening for collaborations with pharmaceutical companies and clinics specializing in these areas to expand treatment options.

Strategic Growth Backing Backed by experienced investors like Linden Capital Partners and HealthQuest Capital, Alcresta has a solid financial foundation for scaling commercial efforts, enabling sales teams to target hospitals, specialty clinics, and distributors with confidence in product growth potential.